PacBio’s second quarter was met with a negative market reaction, as sales and adjusted earnings per share both fell short of Wall Street’s expectations. Management attributed the underperformance to ongoing funding constraints in the U.S. academic and government sectors, as well as a transition period as customers validated the new SPRQ-Nx chemistry. CEO Mark Van Oene, newly appointed after Christian Henry’s departure, stated that “customer enthusiasm for SPRQ-Nx has remained strong since full launch,” but acknowledged that the pace of adoption and inventory dynamics weighed on quarterly results.

Is now the time to buy PACB? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From PacBio’s Q2 Earnings Call

• Kyle Mikson (Canaccord Genuity) asked whether most new Revio and Vega system placements were to clinical customers. CEO Mark Van Oene explained that the majority were clinical accounts, highlighting ongoing momentum in clinical adoption for both instruments.

• Thomas VonDerVellen (Guggenheim) inquired about expected consumables pull-through for the second half as population-scale and clinical customers ramp. Van Oene detailed that consumables revenue would likely remain flat in the next quarter, with growth expected as SPRQ-Nx adoption accelerates later in the year.

• Jack Meehan (Operon Research) questioned gross margin headwinds related to memory supply and when improvements from multi-use SMRT Cells would be realized. CFO James Gibson clarified that memory costs will persist into 2027, with margin benefits from SPRQ-Nx expected to ramp as adoption increases.

• Mason Carrico (Stephens) asked if the SPRQ-Nx cost reduction would lead to higher sample volumes to offset lower pricing. Van Oene responded that customer demand and project scale should close the revenue gap as adoption ramps in the back half of the year.

• Lauren Timmins (Jefferies) probed why full-year guidance was lowered despite positive SPRQ-Nx signals. Van Oene explained that ongoing transition headwinds and elevated compute costs warranted a more cautious outlook.

Catalysts in Upcoming Quarters

In coming quarters, the StockStory team will closely monitor (1) the pace of SPRQ-Nx adoption and its impact on consumables growth, (2) progress in clinical and population-scale project expansion, particularly in EMEA and new customer segments, and (3) the company’s success in mitigating supply chain and manufacturing cost pressures. Operational execution in driving clinical engagement and expanding gross margins will also be key signposts for PacBio’s path forward.

PacBio currently trades at $1.16, down from $1.30 just before the earnings. Is there an opportunity in the stock? Find out in our full research report (it’s free).

High-Quality Stocks for All Market Conditions

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.